Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice

Tracy Y. Wang, Fang-Shu Ou, Matthew T. Roe, Robert A. Harrington, E. Magnus Ohman, W. Brian Gibler, Eric D. Peterson

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background - Prior studies examining thrombocytopenia among patients with acute coronary syndromes (ACS) evaluated highly selected patients in a clinical trial setting using varying definitions of thrombocytopenia. The incidence, severity, and prognostic significance of acquired thrombocytopenia during ACS in community practice have not been well defined. Methods and Results - We examined 36 182 patients with non-ST-segment elevation ACS enrolled at 379 US hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) quality improvement initiative between June 2004 and December 2006. Patients with baseline platelet counts <150×10 9/L were excluded. Overall, 4697 patients (13%) developed new thrombocytopenia, defined as nadir platelet count <150×10 9/L (referenced lower limit of normal), during their ACS hospitalization. Risks of in-hospital mortality and bleeding correlated directly with severity of thrombocytopenia; even mild thrombocytopenia (nadir 100 to 149×10 9/L) was associated with increased risks of mortality (adjusted odds ratio [OR], 2.01; 95% CI, 1.69 to 2.38) and bleeding (adjusted OR, 3.76; 95% CI, 3.43 to 4.12). Each 10% drop in platelet count was associated with increased mortality and bleeding risks (adjusted ORs, 1.39 [95% CI, 1.33 to 1.46] and 1.89 [95% CI, 1.83 to 1.95], respectively). A ≥50% drop in platelet count was associated with higher risk of adverse outcomes regardless of the nadir count. A novel combined definition of acquired thrombocytopenia - nadir <150×10 9/L or platelet count drop ≥50% - identifies a population of ACS patients at higher risk of mortality and major bleeding (adjusted ORs, 2.58 [95% CI, 2.23 to 2.98] and 4.32 [95% CI, 3.97 to 4.70], respectively). Conclusions - Thrombocytopenia, a common complication of ACS, is associated with increased mortality and bleeding risks. Even mild thrombocytopenia or a platelet count drop ≥50% in the setting of normal nadir values is clinically significant. Application of a combined definition for thrombocytopenia using both absolute and relative thresholds permits increased sensitivity for patients at high risk of adverse outcomes.

Original languageEnglish (US)
Pages (from-to)2454-2462
Number of pages9
JournalCirculation
Volume119
Issue number18
DOIs
StatePublished - May 12 2009
Externally publishedYes

Fingerprint

Acute Coronary Syndrome
Thrombocytopenia
Platelet Count
Incidence
Hemorrhage
Mortality
Odds Ratio
Unstable Angina
Quality Improvement
Hospital Mortality
Reference Values
Hospitalization
Clinical Trials
Guidelines

Keywords

  • Acute coronary syndrome
  • Bleeding
  • Thrombocytopenia

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. / Wang, Tracy Y.; Ou, Fang-Shu; Roe, Matthew T.; Harrington, Robert A.; Ohman, E. Magnus; Gibler, W. Brian; Peterson, Eric D.

In: Circulation, Vol. 119, No. 18, 12.05.2009, p. 2454-2462.

Research output: Contribution to journalArticle

Wang, Tracy Y. ; Ou, Fang-Shu ; Roe, Matthew T. ; Harrington, Robert A. ; Ohman, E. Magnus ; Gibler, W. Brian ; Peterson, Eric D. / Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. In: Circulation. 2009 ; Vol. 119, No. 18. pp. 2454-2462.
@article{168b8cba5fb64fb486a99fb0420578c9,
title = "Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice",
abstract = "Background - Prior studies examining thrombocytopenia among patients with acute coronary syndromes (ACS) evaluated highly selected patients in a clinical trial setting using varying definitions of thrombocytopenia. The incidence, severity, and prognostic significance of acquired thrombocytopenia during ACS in community practice have not been well defined. Methods and Results - We examined 36 182 patients with non-ST-segment elevation ACS enrolled at 379 US hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) quality improvement initiative between June 2004 and December 2006. Patients with baseline platelet counts <150×10 9/L were excluded. Overall, 4697 patients (13{\%}) developed new thrombocytopenia, defined as nadir platelet count <150×10 9/L (referenced lower limit of normal), during their ACS hospitalization. Risks of in-hospital mortality and bleeding correlated directly with severity of thrombocytopenia; even mild thrombocytopenia (nadir 100 to 149×10 9/L) was associated with increased risks of mortality (adjusted odds ratio [OR], 2.01; 95{\%} CI, 1.69 to 2.38) and bleeding (adjusted OR, 3.76; 95{\%} CI, 3.43 to 4.12). Each 10{\%} drop in platelet count was associated with increased mortality and bleeding risks (adjusted ORs, 1.39 [95{\%} CI, 1.33 to 1.46] and 1.89 [95{\%} CI, 1.83 to 1.95], respectively). A ≥50{\%} drop in platelet count was associated with higher risk of adverse outcomes regardless of the nadir count. A novel combined definition of acquired thrombocytopenia - nadir <150×10 9/L or platelet count drop ≥50{\%} - identifies a population of ACS patients at higher risk of mortality and major bleeding (adjusted ORs, 2.58 [95{\%} CI, 2.23 to 2.98] and 4.32 [95{\%} CI, 3.97 to 4.70], respectively). Conclusions - Thrombocytopenia, a common complication of ACS, is associated with increased mortality and bleeding risks. Even mild thrombocytopenia or a platelet count drop ≥50{\%} in the setting of normal nadir values is clinically significant. Application of a combined definition for thrombocytopenia using both absolute and relative thresholds permits increased sensitivity for patients at high risk of adverse outcomes.",
keywords = "Acute coronary syndrome, Bleeding, Thrombocytopenia",
author = "Wang, {Tracy Y.} and Fang-Shu Ou and Roe, {Matthew T.} and Harrington, {Robert A.} and Ohman, {E. Magnus} and Gibler, {W. Brian} and Peterson, {Eric D.}",
year = "2009",
month = "5",
day = "12",
doi = "10.1161/CIRCULATIONAHA.108.827162",
language = "English (US)",
volume = "119",
pages = "2454--2462",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "18",

}

TY - JOUR

T1 - Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice

AU - Wang, Tracy Y.

AU - Ou, Fang-Shu

AU - Roe, Matthew T.

AU - Harrington, Robert A.

AU - Ohman, E. Magnus

AU - Gibler, W. Brian

AU - Peterson, Eric D.

PY - 2009/5/12

Y1 - 2009/5/12

N2 - Background - Prior studies examining thrombocytopenia among patients with acute coronary syndromes (ACS) evaluated highly selected patients in a clinical trial setting using varying definitions of thrombocytopenia. The incidence, severity, and prognostic significance of acquired thrombocytopenia during ACS in community practice have not been well defined. Methods and Results - We examined 36 182 patients with non-ST-segment elevation ACS enrolled at 379 US hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) quality improvement initiative between June 2004 and December 2006. Patients with baseline platelet counts <150×10 9/L were excluded. Overall, 4697 patients (13%) developed new thrombocytopenia, defined as nadir platelet count <150×10 9/L (referenced lower limit of normal), during their ACS hospitalization. Risks of in-hospital mortality and bleeding correlated directly with severity of thrombocytopenia; even mild thrombocytopenia (nadir 100 to 149×10 9/L) was associated with increased risks of mortality (adjusted odds ratio [OR], 2.01; 95% CI, 1.69 to 2.38) and bleeding (adjusted OR, 3.76; 95% CI, 3.43 to 4.12). Each 10% drop in platelet count was associated with increased mortality and bleeding risks (adjusted ORs, 1.39 [95% CI, 1.33 to 1.46] and 1.89 [95% CI, 1.83 to 1.95], respectively). A ≥50% drop in platelet count was associated with higher risk of adverse outcomes regardless of the nadir count. A novel combined definition of acquired thrombocytopenia - nadir <150×10 9/L or platelet count drop ≥50% - identifies a population of ACS patients at higher risk of mortality and major bleeding (adjusted ORs, 2.58 [95% CI, 2.23 to 2.98] and 4.32 [95% CI, 3.97 to 4.70], respectively). Conclusions - Thrombocytopenia, a common complication of ACS, is associated with increased mortality and bleeding risks. Even mild thrombocytopenia or a platelet count drop ≥50% in the setting of normal nadir values is clinically significant. Application of a combined definition for thrombocytopenia using both absolute and relative thresholds permits increased sensitivity for patients at high risk of adverse outcomes.

AB - Background - Prior studies examining thrombocytopenia among patients with acute coronary syndromes (ACS) evaluated highly selected patients in a clinical trial setting using varying definitions of thrombocytopenia. The incidence, severity, and prognostic significance of acquired thrombocytopenia during ACS in community practice have not been well defined. Methods and Results - We examined 36 182 patients with non-ST-segment elevation ACS enrolled at 379 US hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) quality improvement initiative between June 2004 and December 2006. Patients with baseline platelet counts <150×10 9/L were excluded. Overall, 4697 patients (13%) developed new thrombocytopenia, defined as nadir platelet count <150×10 9/L (referenced lower limit of normal), during their ACS hospitalization. Risks of in-hospital mortality and bleeding correlated directly with severity of thrombocytopenia; even mild thrombocytopenia (nadir 100 to 149×10 9/L) was associated with increased risks of mortality (adjusted odds ratio [OR], 2.01; 95% CI, 1.69 to 2.38) and bleeding (adjusted OR, 3.76; 95% CI, 3.43 to 4.12). Each 10% drop in platelet count was associated with increased mortality and bleeding risks (adjusted ORs, 1.39 [95% CI, 1.33 to 1.46] and 1.89 [95% CI, 1.83 to 1.95], respectively). A ≥50% drop in platelet count was associated with higher risk of adverse outcomes regardless of the nadir count. A novel combined definition of acquired thrombocytopenia - nadir <150×10 9/L or platelet count drop ≥50% - identifies a population of ACS patients at higher risk of mortality and major bleeding (adjusted ORs, 2.58 [95% CI, 2.23 to 2.98] and 4.32 [95% CI, 3.97 to 4.70], respectively). Conclusions - Thrombocytopenia, a common complication of ACS, is associated with increased mortality and bleeding risks. Even mild thrombocytopenia or a platelet count drop ≥50% in the setting of normal nadir values is clinically significant. Application of a combined definition for thrombocytopenia using both absolute and relative thresholds permits increased sensitivity for patients at high risk of adverse outcomes.

KW - Acute coronary syndrome

KW - Bleeding

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=66549083592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66549083592&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.108.827162

DO - 10.1161/CIRCULATIONAHA.108.827162

M3 - Article

C2 - 19398666

AN - SCOPUS:66549083592

VL - 119

SP - 2454

EP - 2462

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 18

ER -